In view of the above reports, VITT patients have a diverse repertoire of antibodies (platelet-activating and non-activating anti-PF4 antibodies, and antiplatelet antibodies) that may even act synergistically to manifest thrombosis and thrombocytopenia. Here, PF4 is linked to Thrombocytopenia.